Barchart.com
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vincera Pharma Inc (VINC)

Vincera Pharma Inc (VINC)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.6480 +0.0280 (+4.52%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.6230 -0.0250 (-3.86%) 18:47 ET
News & Headlines for Fri, Mar 21st, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI GlobeNewswire - Tue Mar 18, 7:52AM CDT

VINC : 0.6480 (+4.52%)
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives GlobeNewswire - Fri Feb 28, 3:05PM CST

VINC : 0.6480 (+4.52%)
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 GlobeNewswire - Wed Jan 29, 7:00AM CST

VINC : 0.6480 (+4.52%)
Vincerx Pharma, Inc. Announces Reverse Stock Split GlobeNewswire - Thu Jan 23, 3:05PM CST

VINC : 0.6480 (+4.52%)
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish Stocktwits - Mon Dec 30, 2024

Retail sentiment on Stocktwits has remained ‘bullish’ on the stock.

VINC : 0.6480 (+4.52%)
VXF : 177.21 (-0.11%)
VTI : 278.85 (+0.04%)
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. GlobeNewswire - Fri Dec 27, 2024

VINC : 0.6480 (+4.52%)
Vincerx Pharma Announces Cost-Cutting Measures and Exploration of Strategic Alternatives to Advance VIP943 Clinical Development Quiver Quantitative, Inc. - Wed Dec 4, 2024

Vincerx Pharma plans cost-controls and strategic alternatives to advance VIP943, a promising cancer treatment currently in Phase 1 study.Quiver AI SummaryVincerx Pharma, Inc. announced plans to implement...

VINC : 0.6480 (+4.52%)
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials Stocktwits - Wed Dec 4, 2024

The company's plans include a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.

VINC : 0.6480 (+4.52%)
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 GlobeNewswire - Wed Dec 4, 2024

VINC : 0.6480 (+4.52%)
Vincerx Pharma Reports Third Quarter 2024 Financial Results GlobeNewswire - Tue Nov 12, 2024

VINC : 0.6480 (+4.52%)

Barchart Exclusives

Economic Growth Data, PMI Reports and Other Can't Miss Items this Week Barchart - 21 minutes ago
Last week saw markets navigate the triple witching expiration amid continued focus on trade tensions and the Federal Reserve's latest policy projections. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals
Wed, Mar 26, 2025 5:00 PM UTC
Reserve Your Spot